Personalis, Inc. (PSNL)
| Market Cap | 202.24M |
| Revenue (ttm) | 79.84M |
| Net Income (ttm) | -81.03M |
| Shares Out | 45.45M |
| EPS (ttm) | -1.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 239,824 |
| Open | 4.13 |
| Previous Close | 4.11 |
| Day's Range | 4.09 - 4.47 |
| 52-Week Range | 3.94 - 28.47 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | 20.40 (+358.4%) |
| Earnings Date | May 4, 2022 |
About PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT D...
Financial Performance
In 2021, Personalis's revenue was $85.49 million, an increase of 8.70% compared to the previous year's $78.65 million. Losses were -$65.23 million, 58.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for PSNL stock is "Buy." The 12-month stock price forecast is 20.4, which is an increase of 358.43% from the latest price.
News
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of -10.53% and 2.61%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Personalis Reports First Quarter 2022 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter ended March 31, 2022. F...
Personalis to Present at Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the following investor conference...
Evaxion to Utilize Personalis' ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Mel...
MENLO PARK, Calif. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis' ImmunoID NeXT Platform in...
Personalis Expands Diagnostic Leadership Team With Appointment of James Azzaro, Vice President of Diagnostic Sales
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the appointment of James Azzaro to the newly created position ...
Personalis to Announce First Quarter 2022 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2022 financial results on Wednesday...
Personalis Publishes New Data Demonstrating Highly Sensitive Algorithm for Detecting Loss of Heterozygosity in HLA Gene
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of its study titled, "A machine learning algor...
Personalis Announces Issuance of Additional US Patent Related to the NeXT Personal™ Platform
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced the issuance of a key US Patent related to its industry-leading minimal residual...
Personalis and Merck KGaA, Darmstadt, Germany to Present Comprehensive Tumor Subtyping Collaboration Data at AACR Ann...
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced its co-authorship of a study with Merck KGaA, Darmstadt, Germany, a ...
Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21st Annual Needham Virtual H...
Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors
MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been appointed as Persona...
Personalis to Present Data Demonstrating Breadth of NeXT Platform for Oncology at AACR Annual Meeting 2022
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced it is presenting new data in scientific posters at the American Asso...
Personalis (PSNL) Reports Q4 Loss, Lags Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of 11.76% and 0.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Personalis Reports Fourth Quarter and Full Year 2021 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the fourth quarter and full year ended De...
Personalis to Present at the Cowen 42nd Annual Health Care Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the Cowen 42nd Annual Health Care...
Earnings Preview: Personalis (PSNL) Q4 Earnings Expected to Decline
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research i...
MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Announces Collaboration with UC San Diego Moores Cancer Center for Clinical Genomic Testing and Research
Personalis to Announce Fourth Quarter and Full-Year Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its fourth quarter and full-year 2021 financial resul...
Personalis to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the BTIG MedTech, Digital Health,...
Personalis Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quar...
Personalis to Participate in the 24th Annual Needham Virtual Growth Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24th Annual Needham Virtual Gr...
Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-P...
MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Launches NeXT Personal™, A Tumor-Informed Liquid Biopsy Assay for MRD and Recurrence Detection With Part-Per-Million Sensitivity
Personalis to Participate in the 33rd Annual Piper Sandler Virtual Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 33rd Annual Piper Sandler Virt...
Personalis Named to Inc.'s 2021 Best-Led Companies List
MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis Named to Inc.'s 2021 Best-Led Companies List
Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
MENLO PARK, Calif.--(BUSINESS WIRE)-- #biomarkers--Personalis to Present New Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting